The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are:
* Does clascoterone improve the severity of pilonidal disease as scored by a physician?
* Does clascoterone improve patient symptoms due to pilonidal disease?
* Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Participants will apply clascoterone or a placebo cream to the diseased area for 3 months. They will be assessed every 4 weeks for disease severity assessed by a physician viewing patient photos and a symptom-based survey.
Researchers will compare participants who received clascoterone treatment to those who received placebo.

Start Date10 Jan 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06454708

/ CompletedPhase 1

An Open Phase I Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Dose and Repeat Dose Topical Administrations of Clascoterone Cream, 1% in Healthy Chinese Adult Subjects

The primary objective of this study is to determine the pharmacokinetics (PK) of Clascoterone Cream, 1% after single dose and repeat dose topical administrations in healthy Chinese adult subjects.

Start Date01 Aug 2024

Sponsor / Collaborator

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

100 Clinical Results associated with Clascoterone

100 Translational Medicine associated with Clascoterone

100 Patents (Medical) associated with Clascoterone

Literatures (Medical) associated with Clascoterone

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of oral isotretinoin monotherapy compared to combination isotretinoin and topical clascoterone for severe acne vulgaris: a multi-center retrospective study

Article

Author: Abu-Hilal, Mohannad ; Cy, Ajith ; Bawazir, Mohamed ; Metko, Dea ; Xiong, Grace ; Choi, UYeong ; Pathayappura, Smitha

INTRODUCTION:

Severe nodular acne causes significant psychological distress and reduces quality of life. Clascoterone 1% cream, a novel anti-androgen with a favorable safety profile, may enhance the efficacy of oral isotretinoin, the gold-standard therapy for severe acne. This study compared isotretinoin monotherapy with isotretinoin plus topical clascoterone 1% cream.

METHODS:

Since June 2023, patients with severe/nodular acne at university-affiliated dermatology clinics were treated with isotretinoin, alone or combined with clascoterone 1% cream twice daily. In December 2024, records were retrospectively reviewed. The analysis included patients aged ≥12 years with severe/nodular acne who received isotretinoin (0.5-0.8 mg/kg/day) with or without clascoterone 1% cream for ≥24 weeks. Outcomes included facial lesion count, Investigator's Global Assessment (IGA), and facial xerosis at week 24.

RESULTS:

Eighty-two patients (44 monotherapy; 38 combination therapy) were included. Both groups showed significant reduction in facial lesion count (p < 0.001), but between-group differences were not significant. More patients in the combination group achieved IGA 0/1 (92.1% vs. 72.7%; p < 0.05). Xerosis rates were lower in the combination group (84% vs. 91%) but not statistically significant.

CONCLUSION:

Clascoterone 1% cream may enhance isotretinoin efficacy without worsening adverse effects, offering a promising approach for severe/nodular acne. Further studies are needed to confirm long-term benefits.

24 Jun 2025·Clinical Pharmacology in Drug Development

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early-Phase Clinical Study Participants.

Article

Author: Kopeloff, Iris ; Squittieri, Nicholas ; Garhöfer, Gerhard ; Mazzetti, Alessandro ; Radicioni, Milko Massimiliano ; Müller, Markus ; Cartwright, Martina ; Moro, Luigi ; Di Stefano, Andrea Francesco Daniele

Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne. Studies CB-03-01/02 (EudraCT: 2007-005064-28) and CB-03-01/04 (n = 24 each) assessed PK in healthy participants. Study 171-7151-203 (n = 8) assessed steady-state PK in patients with acne. Studies CB-03-01/05 (n = 36) and CB-03-01/32 (n = 250) assessed skin irritation and sensitization potential, respectively, in healthy participants. Systemic exposure to clascoterone was low after repeated daily application for up to 42 days of treatment. Clascoterone was excreted in urine as conjugated esters at a ≤1% fraction of the administered dose. Adverse events and local skin reactions were generally mild/moderate and reversible. No clinically relevant changes were observed in laboratory tests and vital signs. Skin irritation and sensitization with clascoterone treatment were minimal. Phase 1 study findings supported low systemic absorption of clascoterone and a favorable safety profile after topical application of clascoterone cream 1%, with no evidence of irritation or sensitization.

01 Apr 2025·Journal of Drugs in Dermatology

Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%

Article

Author: Kyeremateng, Kizito ; Squittieri, Nicholas ; D. Draelos, Zoe

BACKGROUND:

Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This study aimed to evaluate the effects of clascoterone cream 1% on skin barrier properties in acne-prone individuals.

METHODS:

Participants ≥18 years of age with acne-prone skin were enrolled in a single-center, split-face study and randomized to twice-daily treatment with clascoterone cream 1% (approximately 0.5 g) to the right or left side of the face for 2 weeks. The primary and secondary endpoints were the changes in corneometry reading and transepidermal water loss (TEWL), respectively, between treated and untreated sides at week 2. Tolerability was evaluated from the severity of dryness, erythema, scaling, irritation, tightness, stinging, itching, and burning for each side using a 5-point scale from 0 (none) to 4 (severe).

RESULTS:

This study enrolled 50 participants (female, n = 38) with a mean ± standard deviation (SD) age of 31.1 ± 8.9 years. The mean ± SD corneometry reading was significantly higher for the treated vs untreated side at week 2 (131.3 ± 42.9 vs 113.9 ± 36.6; P<0.001). There was no difference in TEWL between treated and untreated sides at any time point assessed. All tolerability parameters evaluated were rated as absent or minimal through week 2 for both sides.

CONCLUSION:

Twice-daily treatment with clascoterone cream 1% for 2 weeks was associated with increased moisturization and maintenance of skin barrier function as assessed by corneometry and TEWL and was otherwise well tolerated. J Drugs Dermatol. 2025;24(4):397-402. doi:10.36849/JDD.8774.

News (Medical) associated with Clascoterone

04 Jun 2025

·www.fiercebiotech.com

Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators

The idea behind denifanstat is to decrease cytokine secretion in order to inhibit the production of facial sebum.\n Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced drug can hold its own against FDA-approved products like Seysara and doxycycline.The Chinese study saw 480 patients with moderate to severe acne vulgaris receive either a once-daily 50-mg dose of the oral fatty acid synthase inhibitor denifanstat or placebo for 12 weeks. The trial hit all three of its primary endpoints, including a 18.6% placebo-adjusted increase in the proportion of patients who achieved success as defined by a skin clearance score.Specifically, 33.2% of patients receiving denifanstat were assessed as having clear or almost clear skin at Week 12, compared to 14.6% of patients on placebo.The average reduction in skin lesions in the denifanstat group was 57.4% compared to 35.4% for those on placebo. When it came to a reduction in inflammatory lesions, the drop was 63.5% and 43.2%, respectively.While the trial was not designed to make head-to-head comparisons with existing acne products, Ascletis laid out its data alongside past results for potential competitors. This included comparing denifanstat’s 18.6% placebo-adjusted treatment success to 9.4% for Almirall’s Seysara, doxycycline’s 6.7% and 11.6% for clascoterone cream.Ascletis pointed to these comparisons as evidence that denifanstat “has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile.”As an oral option, Ascletis also hopes denifanstat could ensure better adherence from patients than the current crop of topical treatments.When it came to safety, the denifanstat and placebo cohorts had a similar profile, the biotech said. The only treatment-related adverse events that affected slightly more than 5% of patients in the denifanstat arm were dry skin and dry eye. The idea behind denifanstat is to decrease cytokine secretion in order to inhibit the production of facial sebum, which is an underlying cause of acne. It means that, unlike some other acne treatments, denifanstat doesn’t have the potential to lead to antibiotic resistance or the off-target effects that can be seen with tetracycline antibiotics, Ascletis said.“We are extremely pleased with the topline results of our phase 3 trial,” Ascletis CEO Jinzi Jason Wu, Ph.D., said in the release.“Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count,” Wu added. “We are excited to be submitting this innovative treatment with the China National Medical Products Administration soon.”Ascletis licensed the China rights to denifanstat from Sagimet back in 2019 with the initial aim of exploring the drug in a liver disease called metabolic dysfunction-associated steatohepatitis. Work on this indication appears to have stalled, with Ascletis stating in March that the company will “make further assessment and seek opportunities to maximize the value of this program.”Antiviral, cancer and liver disease drug candidates were central to Ascletis’ strategy when the company went public in 2018. However, the biotech suffered setbacks in the clinic in its original core areas, including axing hepatitis B and liver disease programs. More recently, Ascletis has unveiled and quickly advanced a weight loss pipeline that features oral and subcutaneous formulations of a GLP-1 receptor agonist, leading the biotech to formalize its pivot to metabolic disease earlier this year.

Clinical ResultPhase 3

03 Jun 2025

·www.prnewswire.com

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Notes: (1) All efficacy endpoints are least square means. (2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA (). (2) The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6. (3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit . Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] SOURCE Ascletis Pharma Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Clinical Result

10 Feb 2025

·pharma.economictimes.indiatimes.com

UK regulator approves Glenmark, Cosmo acne treatment

New Delhi: Cosmo Pharmaceuticals and Glenmark announced that they have received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to market Winlevi , a topical treatment for acne vulgaris in patients aged 12 years and old. Winlevi is a topical androgen receptor inhibitor , targeting androgen receptors in sebaceous glands with no systemic anti-androgen effects, and as such it can be used safely in both males and females, the company stated. As part of the agreement signed in September 2023, Glenmark has in-licensed the product from Cosmo Pharmaceuticals for distribution in Europe and South Africa. “Our partnership with Cosmo Pharmaceuticals plays an important role in enabling us to expand our dermatology portfolio, and we are proud to offer this new treatment to market that can improve the quality of life for those living with acne,” said Christoph Stoller, President & Business Head - Europe and Emerging Markets, Glenmark Pharmaceuticals . By Online Bureau ,

Drug Approval

100 Deals associated with Clascoterone

External Link

KEGG	Wiki	ATC	Drug Bank
D11451	Clascoterone	G03HA	DB12499

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acne Vulgaris	United States	Sun Pharmaceutical Industries Ltd.	26 Aug 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia, Male Pattern	Phase 3	United States	Cassiopea SpA	21 Jun 2023
Alopecia, Male Pattern	Phase 3	Georgia	Cassiopea SpA	21 Jun 2023
Androgenetic Alopecia	Phase 3	United States	Cassiopea SpA	21 Jun 2023
Androgenetic Alopecia	Phase 3	Georgia	Cassiopea SpA	21 Jun 2023
Rosacea	Phase 2	United States	Sun Pharmaceutical Industries Ltd.	14 Mar 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06336629 (CTgov)	Phase 4	Acne Vulgaris	10	Winlevi	fslgrxzhcv = huuzfgpswj uxcsyixwdb (rqfkqpzqwd, qnbvhcgezj - rsvghdjsiw) View more	-	17 Jul 2025
NCT06415305 (CTgov)	Phase 4	Acne Vulgaris	10	Winlevi (clascoterone) 1% cream	zhdxyekohc = kukzrmmqdn ggbdjelivt (mfdqmsxvvl, oqtqxyzdny - yivybrrdsb) View more	-	07 May 2025
Health Canada Manual	Phase 3	Acne Vulgaris	1,421	WINLEVI (Trial 1)	brnixiqfom(nnmzawcbap) = vrhddnccxp ahpdhdxsnp (euvzzeaxiy ) View more	Positive	08 Sep 2023
				Vehicle (Trial 1)	brnixiqfom(nnmzawcbap) = pxcnznnmak ahpdhdxsnp (euvzzeaxiy ) View more
NCT02682264 (AAD2023)	Phase 3	Acne Vulgaris	598	Clascoterone cream 1%	jsouwyqief(yaqyfforum) = tewpwsonbt qdkuiaquaj (knxcgtyhsa ) View more	-	17 Mar 2023
AAD2023	Phase 3	Acne Vulgaris	-	Clascoterone cream 1%	iixnydjdik(couxrqwenl) = lnvputhaxt ogtwmpccgu (qmtgddzjhl )	-	17 Mar 2023
				Vehicle	iixnydjdik(couxrqwenl) = lfjxzykveq ogtwmpccgu (qmtgddzjhl )
NCT02608476 (CB-03-01/26, CTgov)	Phase 3	Acne Vulgaris	732	CB-03-01 cream, 1% (CB-03-01 Cream)	cfrddhzvlg = juarkqhbbc eohcjqfepr (mbpflgpchb, pfphlsbuzg - jtztlhcqoz) View more	-	20 Nov 2020
				Vehicle cream (Vehicle Cream)	cfrddhzvlg = gpdmrypidl eohcjqfepr (mbpflgpchb, hmjdvzjjoj - febtuaesmg) View more
NCT02608450 (CB-03-01/25, CTgov)	Phase 3	Acne Vulgaris	708	CB-03-01 cream, 1% (CB-03-01 Cream)	wiowdzdpcl = hsubgwxtpg fjooaetfwt (prbquiszdd, jdcwzxgorl - lzyeqzsavi) View more	-	20 Nov 2020
				Vehicle cream (Vehicle Cream)	wiowdzdpcl = hzstyiocfg fjooaetfwt (prbquiszdd, uylymopgtv - rooeibwxgq) View more
NCT02682264 (CTgov)	Phase 3	Acne Vulgaris	609	CB-03-01 cream, 1%	axnwbwtfhr = emdojpofcb spbvxuzkce (aaizaxpmrg, piouvgdzwn - kupxwsdczq) View more	-	17 Nov 2020
NCT01831960 (CTgov)	Phase 2	Acne Vulgaris	42	Cortexolone 17α-Propionate (Cortexolone 17α-Propionate (Cohort 1))	qziaratimd(kthvzjcwka) = riiwgodzzv zninvemgrq (ivxnzimcuh, 5.98) View more	-	17 Nov 2020
				Cortexolone 17α-Propionate (Cortexolone 17α-Propionate (Cohort 2))	qziaratimd(kthvzjcwka) = nnklvksift zninvemgrq (ivxnzimcuh, 4.71) View more
NCT01631474 (CTgov)	Phase 2	Acne Vulgaris	363	CB-03-01 (Low-dose Active, BID)	hdwimvhbfx = ftdmwfowiu bvkbmbdphj (almpnyczdk, ixcbepsbvs - hhiezuwqeu) View more	-	16 Nov 2020
				CB-03-01 (Medium-dose Active, BID)	hdwimvhbfx = bhqqocqxvi bvkbmbdphj (almpnyczdk, pcqdugayct - imjvqzazjd) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis